Thromboembolic disease markers
The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.
1. A method comprising:
a) determining in a sample isolated from a human subject the presence or absence of each of the following polymorphisms:
Serpin A10 (protein Z inhibitor) Arg67Stop (rs2232698),
Serpin CI (antithrombin) Ala384Ser (Cambridge II),
factor XIIC46T (rsl801020),
factor XIII Va134Leu (rs5985),
Factor II (prothrombin) G20210A (rsl799963),
factor V Leiden Arg506Gln (rs6025),
factor V Cambridge Arg306Thr,
factor V Hong Kong Arg306Gly,
ABO blood group rs8176719,
ABO blood group rs7853989,
ABO blood group rs8176743, and
ABO blood group rs8176750;
b) detecting the presence of at least one of said polymorphisms in said subject;
c) identifying the subject with at least one of said polymorphisms for treatment and
d) administering to the subject identified in step c) an anticoagulant and/or antithrombotic therapy.
2. The method according to claim 1 , further comprising determining one or more cardiovascular disease or disorder risk factors in the human subject selected from the group consisting of age, race, sex, body mass index, smoking status, systolic blood pressure, diastolic blood pressure, hospitalization, plaster cast immobilization, surgery, trauma, oral contraceptives or hormone therapy, pregnancy, prolonged travel (≥2 hours), collagen vascular diseases, heart failure, malignancy, medications, myelo proliferative disorders, nephrotic syndrome, recurrent pregnancy loss, abdominal obesity, diabetes mellitus, low density lipoprotein (LDL)-cholesterol level, high density lipoprotein (HDL)-cholesterol level, cholesterol level, triglyceride levels, family history of thromboembolic event, pregnancy, and body mass index.
3. The method according to claim 1 , wherein the sample is an oral tissue sample, scraping, or wash or a biological fluid sample.
4. The method of claim 3 , wherein the sample is saliva, urine or blood.
5. The method according to claim 1 , wherein the presence or absence of the polymorphism is identified by amplifying or failing to amplify an amplification product from the sample.
6. The method according to claim 5 , wherein the amplification product is digested with a restriction enzyme before analysis.
7. The method according to claim 1 , wherein the polymorphism is identified by hybridizing nucleic acid in the sample with a primer label which is a detectable moiety.
8. The method according to claim 1 , where in the subject has a thromboembolic disease selected from the group of fatal or non-fatal myocardial infarction, stroke, transient ischemic attacks, peripheral arteriopathy, vein thrombosis, deep vein thrombosis, pulmonary embolism or a combination thereof.
9. The method according to claim 1 , wherein the anticoagulant and/or antithrombotic therapy comprises administering to the subject heparins, a vitamin K antagonist, direct thrombin inhibitor, factor Xa inhibitor.
10. The method according to claim 9 , wherein the vitamin K antagonist is Warfarin.
11. The method according to claim 9 , wherein the direct thrombin inhibitor is argatroban, lepirudin, desirudin, bivalirudin, Dabigatran etexilate or Dabigatran.
12. The method according to claim 9 , wherein the factor Xa inhibitor is fondaparinux, rivaroxiban, betrixaban, edoxaban, otamixaban, letaxaban, eribaxaban, or apixaban.
13. The method of claim 1 , wherein the presence of at least two polymorphisms are detected in the subject.